Abstract
Background Angiotensin (Ang)-II impairs the function of the antihypertensive enzyme ACE2 by promoting its internalization, ubiquitination and degradation thus contributing to hypertension. However, few ACE2 ubiquitination partners have been identified and their role in hypertension remains unknown.
Methods Proteomics and bioinformatic analysis were used to identify ACE2 ubiquitination partners in the brain, heart, and kidney from Ang-II-infused C57BL6/J mice from both sexes and validated the interaction between UBR1 and ACE2 in cells. Central and peripheral UBR1 knockdown was then performed in male mice to investigate its role in the maintenance of hypertension.
Results Proteomics analysis from hypothalamus identified UBR1 as a potential E3 ligase promoting ACE2 ubiquitination. Enhanced UBR1 expression, associated with ACE2 reduction, was confirmed in various tissues from hypertensive male mice and human samples. Treatment of endothelial and smooth muscle cells with testosterone, but not 17β-estradiol, confirmed a sex-specific regulation of UBR1. In vivo silencing of UBR1 using chronic administration of small interference RNA resulted in the restoration of ACE2 levels in hypertensive males. A transient decrease in blood pressure following intracerebroventricular, but not systemic, infusion was also observed. Interestingly, UBR1 knockdown increased the brain activation of Nedd4-2, an E3 ligase promoting ACE2 ubiquitination and reduced expression of SGK1, the kinase inactivating Nedd4-2. Conclusions: These data demonstrate that UBR1 is a novel ubiquitin ligase targeting ACE2 in hypertension. UBR1 and Nedd4-2 E3 ligases appear to work synergistically to ubiquitinate ACE2. Targeting of these ubiquitin ligases may represent a novel strategy to restore ACE2 compensatory activity in hypertension.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by research grants from the National Institutes of Health (HL150592 to E.L. and C.M.F. and CoBRE P30GM106392), the United States Department of Veterans Affairs (Biomedical Laboratory Research and Development Service, Merit Award I01 BX004294), and the Research Enhancement Program at LSU Health-NO
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cardiac samples from patients were obtained from The Medical College of Wisconsin (IRB #PRO00010828) and Duke University (IRB #PRO00005621) from organs not suitable for transplant. Informed consents were obtained prior to experiments and all procedures conform to the principles outlined in the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Nonstandard Abbreviation and Acronyms
- ACE2
- Angiotensin Converting Enzyme 2
- Ang-II
- Angiotensin II
- Ang-(1-7)
- Angiotensin (1-7)
- ANOVA
- Analysis of variance
- AT1R
- Ang-II type 1 receptor
- BP
- Blood pressure
- DHT
- dihydrotestosterone
- DBDi
- androgen receptor (AR) DNA-binding domain inhibitor
- E1
- Ubiquitin-activating enzymes
- E2
- Ubiquitin-conjugating enzymes
- E3
- Ubiquitin protein ligases
- ENaC
- Kidney epithelial Na+ channels
- HAEC
- Human aortic endothelial cells
- LC-MS
- Liquid chromatography–mass spectrometry
- MAP
- Mean arterial pressure
- MDM2
- Murine double minute 2
- MPP
- Methylpiperidinopyrazole
- Nedd4-2
- Neural Precursor Cell Expressed Developmentally Down-Regulated Protein 4
- PHTPP
- 4-[2-PHENYL-5,7-BIS(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]PHENOL
- RAS
- Renin-angiotensin system
- Skp2
- S-Phase Kinase Associated Protein 2
- siRNA
- Small interfering RNA
- SMC
- Smooth muscle cell
- SGK1
- Serum/Glucocorticoid-Regulated Kinase 1
- UBR1
- Ubiquitin Protein Ligase E3 Component N-Recognin
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos